Escitalopram cuts MACE risk in depressed patients with ACS

(HealthDay)—For patients with depression following recent acute coronary syndrome (ACS), escitalopram results in lower risk of major adverse cardiac events (MACE) versus placebo, according to a study published in the July ...

Psychology & Psychiatry

Genetic analysis can improve depression therapy

The failure of drugs such as SSRIs, used to treat depression, can be a result of genetic variations in patients. Variations within the gene that encodes the CYP2C19 enzyme results in extreme differences in the levels of escitalopram ...


Brain stimulation no better than escitalopram for depression

(HealthDay)—Escitalopram may outperform transcranial direct-current stimulation (tDCS) in the treatment of depression, according to a study published in the June 29 issue of the New England Journal of Medicine.


First generic lexapro approved

(HealthDay) -- The Israeli drug maker Teva Pharmaceuticals has gained the first U.S. approval to market generic Lexapro (escitalopram) to treat depression and general anxiety disorder, the U.S. Food and Drug Administration ...

Psychology & Psychiatry

Researchers develop biomarker for rapid relief of major depression

( -- It is a long, slow slog to treat major depression. Many antidepressant medications are available, but no single biomarker or diagnostic test exists to predict which one is right for an individual. As a result, ...